The Food and Drug Administration approved a new coronavirus vaccine from the manufacturer Novavax, who created a more traditional protein-based formula versus the three currently approved mRNA versions, CNBC reports.
In the emergency authorization, the FDA approved the Novavax vaccine for patients 18 and over, adding another weapon to the quiver of physicians trying to protect patients from the coronavirus. Novavax used more than $1.8 billion in funding under the Trump Administration’s Operation Warp Speed, doled out two years ago, to develop the vaccine.
Officials hope the fact that this vaccine is a more traditional formulation will encourage many of the 25% of American adults who have not received a single vaccine inoculation out of fear of the new technology used to develop the mRNA vaccines.